Welcome to LookChem.com Sign In|Join Free
  • or
5-cyano-2-methoxybenzoic acid is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

84923-71-7

Post Buying Request

84923-71-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

84923-71-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 84923-71-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,4,9,2 and 3 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 84923-71:
(7*8)+(6*4)+(5*9)+(4*2)+(3*3)+(2*7)+(1*1)=157
157 % 10 = 7
So 84923-71-7 is a valid CAS Registry Number.

84923-71-7Relevant academic research and scientific papers

Rational approach to highly potent and selective apoptosis signal-regulating kinase 1 (ASK1) inhibitors

Lovering, Frank,Morgan, Paul,Allais, Christophe,Aulabaugh, Ann,Brodfuehrer, Joanne,Chang, Jeanne,Coe, Jotham,Ding, WeiDong,Dowty, Heather,Fleming, Margaret,Frisbie, Richard,Guzova, Julia,Hepworth, David,Jasti, Jayasankar,Kortum, Steve,Kurumbail, Ravi,Mohan, Shashi,Papaioannou, Nikolaos,Strohbach, Joseph W.,Vincent, Fabien,Lee, Katherine,Zapf, Christoph W.

, p. 606 - 621 (2018/01/19)

Many diseases are believed to be driven by pathological levels of reactive oxygen species (ROS) and oxidative stress has long been recognized as a driver for inflammatory disorders. Apoptosis signal-regulating kinase 1 (ASK1) has been reported to be activ

COMPOUNDS AND METHODS for the inhibition of HDAC

-

Paragraph 0427-0428; 0817-0818, (2015/11/24)

Disclosed are compounds having the formula: wherein X1, X2, X3, R1, R2, R3, R4, Y, A, Z, L and n are as defined herein, and methods of making and using the same.

NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS

-

Page/Page column 74, (2010/06/11)

The present application relates to isothiazolylidene containing compounds of Formula (I) wherein R1, R2, R3, R4, and L are as defined in the specification, compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions.

NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS

-

, (2008/12/08)

The present application relates to isothiazolylidene containing compounds of Formula (I) wherein R1, R2, R3, R4, and L are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS

-

Page/Page column 25, (2008/12/09)

The present application relates to thiazolylidene containing compounds of formula (I) wherein R1, R2, R3, and R4 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS

-

Page/Page column 36, (2008/12/07)

The present application relates to thiazolylidene containing compounds of formula (I) wherein R1, R2, R3, R4, L2 and A are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

PHARMACEUTICAL COMPOUNDS

-

Page/Page column 205-206, (2010/11/28)

The use of a compound for the manufacture of a medicament for the prophylaxis or treatment of: A. a disease state or condition mediated by a kinase which is BCR-abl, VEGFR, PDGFR, EGFR, Flt3, JAK (e.g. JAK2 or JAK3), C-abl, PDKl , Chk (e.g. Cbkl or Chk2),

BENZAMIDE DERIVATIVE

-

Page/Page column 78-79, (2010/11/23)

To provide compounds which have high angiogenesis inhibiting activity, and are useful as agents for effective treatment and prevention of diseases involving pathologic angiogenesis, for example, cancer and cancer metastasis, methods for producing the comp

PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES

-

Page/Page column 146-147, (2008/06/13)

The invention provides a compound of the formula (I): or a salt, solvate, tautomer or N-oxide thereof, wherein M is selected from a group D1 and a group D2: and R', E, A and X are as defined in the claims. Also provided are pharmaceutical compositions con

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 84923-71-7